
What Does It Take to Build a Business Around a Single Patient?
Emerging “N-of-1” Models and the Regulatory Road Ahead
Advances in genetic testing and personalized medicine are creating new opportunities for individualized, or “N-of-1,” therapies. As emerging companies explore scalable business models for these treatments, they face evolving regulatory, legal, and ethical considerations that will shape their development and commercialization.
Emerging “N-of-1” Models and the Regulatory Road Ahead
Treasury Proposes to Prohibit U.S. Investment in Chinese Biotech: What It Means for China Licensing Deals
On October 26, 2026, the U.S. Treasury Department published proposed regulations (new 31 C.F.R. Part 851) in the Federal Register implementing the Comprehensive Outbound Investment National Security Act (COINS Act). The proposed regulations would prohibit investments by U.S. persons in Chinese biotechnology companies involved in the development or production of small molecules, biologics, vaccines, cell and gene therapies, and their delivery mechanisms where a biological system is used to modify, enhance, produce, or control them. The regulations also prohibit U.S. persons from establishing joint ventures with Chinese partners to conduct such activities. For companies that in-license drug candidates from Chinese biotechs, the license itself remains permitted, but several deal features that are now market practice (licensor equity, NewCos, profit-share collaborations, and certain governance terms) would carry real risk. Comments are due December 7, 2026. The rule is not yet effective. The “effective date” referenced below is the date of the entry into force of the new regulations, which is likely to be close to the end of the first quarter of 2027.
